BioLineRx Ltd.

Tel Aviv Stock Exchange:BLRX.TA

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Pharmaceuticals

Location

Israel

Market Cap

USD 16.61 M

Share Price

USD 0.01

Avg Daily Volume

6,380,309

Change (1 day)

-0.26%

Change (1 year)

-82.37%

Change (YTD)

-56.73%

BioLineRx Ltd. Total Assets for the year ending December 31, 2024: USD 38.91 M

BioLineRx Ltd. Total Assets is USD 38.91 M for the year ending December 31, 2024, a -39.14% change year over year. Total assets are the total value of all assets owned by a company, representing its resources.

BioLineRx Ltd. Total Assets for the year ending December 31, 2023 was USD 63.92 M, a -16.31% change year over year.
BioLineRx Ltd. Total Assets for the year ending December 31, 2022 was USD 76.38 M, a -6.15% change year over year.
BioLineRx Ltd. Total Assets for the year ending December 31, 2021 was USD 81.39 M, a 72.11% change year over year.
BioLineRx Ltd. Total Assets for the year ending December 31, 2020 was USD 47.29 M, a -11.72% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Total Assets	Accounts Payable	Short-Term Debt	Long-Term Debt

Tel Aviv Stock Exchange: BLRX.TA

BioLineRx Ltd.

CEO	Mr. Philip A. Serlin CPA, CPA, M.B.A., MBA
IPO Date	April 4, 2007
Location	Israel
Headquarters	Modi’in Technology Park
Employees	28
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Pharmaceuticals

Description

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.